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ABSTRACT
Objective: To investigate the blood-CSF barrier (BCSFB) dysfunction in aseptic meningitis.
Methods: In our case series of 14 patients with acute aseptic meningitis, we compared MRI
characteristics with CSF findings.
Results: Contrast enhancement in the sulcal space in a leptomeningeal pattern was visualized
in 7 patients with BCSFB dysfunction categorized as moderate to severe as evidenced by the
CSF/serum albumin ratio (Qalb) but was not present in those with mild or no barrier disturbance
(p 5 0.001). The Qalb as a marker for the leakiness of the BCSFB and, more indirectly, of the
blood-brain barrier (BBB) was positively correlated with the incidence of leptomeningeal contrast
enhancement seen on postcontrast fluid-attenuated inversion recovery (FLAIR) MRI (p 5 0.003).
Patients with a more pronounced brain barrier dysfunction recovered more slowly and stayed
longer in the hospital.
Conclusions: The severity of meningeal BBB disturbance can be estimated on postcontrast FLAIR
MRI, which may be of diagnostic value in patients with aseptic meningitis. Neurol Neuroimmunol
Neuroinflamm 2015;2:e164; doi: 10.1212/NXI.0000000000000164
GLOSSARY
BBB5 blood-brain barrier; BCSFB 5 blood-CSF barrier; CMV 5 cytomegalovirus; FLAIR5 fluid-attenuated inversion recov-
ery; HSV5 herpes simplex virus; Qalb 5 CSF/serum albumin ratio; QIgG5 CSF/serum IgG ratio; VZV5 varicella-zoster virus.
The term “aseptic meningitis” encompasses nonbacterial inflammation syndromes of the
meninges predominantly caused by viral infections.1 All viral pathogens share a common step
in their pathophysiology when traversing brain barriers followed by penetration into the CNS.
In their function to maintain CNS homeostasis, blood-brain barrier (BBB) endothelial cells also
restrict the entry of both pathogens and immune cells. Meningeal CNS microvessels on the
surface of the brain also establish a barrier with somewhat different morphology in order to
separate the CSF-drained leptomeningeal space from the blood.2 In viral meningitis, disruption
of the brain barriers occurs mostly via indirect effects of the virus on the immune system,
including induction of chemokines and cytokines and leukocyte homing, among others.3 Dis-
integration of the brain barriers, in turn, can lead to efficient viral clearance by enhanced
infiltration of immune cells into the CNS but may also cause a fatal clinical course with prop-
agation to encephalitic involvement and entry of deleterious serum molecules into the brain
parenchyma.
The diagnosis of meningitis is based on the combination of typical clinical symptoms and
positive CSF findings. Whereas an increase in CSF leukocyte count reflects the inflammatory
reaction with transmigration of immune cells into the CSF, the CSF/serum albumin ratio (Qalb)
indicates a leakage of blood-borne proteins due to blood-CSF barrier (BCSFB) dysfunction and,
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more indirectly, BBB dysfunction. MRI is
commonly used to evaluate complications such
as encephalitic involvement, hydrocephalus, or
cerebral vasculitis with subsequent ischemia.
However, recent work has highlighted the role
of postcontrast fluid-attenuated inversion
recovery (FLAIR) imaging in the detection of
leptomeningeal pathologies, including menin-
gitis or meningeal carcinomatosis.4 Mainly due
to the suppression of CSF signal, postcontrast
FLAIR images show a higher sensitivity in
delineation of meningeal pathologies.5
In our study, we sought to compare CSF
findings with postcontrast FLAIR findings in
patients with aseptic meningitis.
METHODS In our case series, we analyzed 14 patients from
our MRI and clinical database admitted between 2011 and
2014 with CSF-confirmed diagnosis of aseptic meningitis.
Clinical data including age, sex, presenting symptoms and
clinical course, duration of hospitalization, medication, and neu-
rologic status at discharge were collected in all patients. Routine
CSF analyses included leukocyte count, CSF protein concentra-
tion, Qalb, CSF/serum IgG ratio (QIgG), CSF culture, CSF serol-
ogy (herpes simplex virus [HSV] IgG/IgM, varicella-zoster virus
[VZV] IgG/IgM, measles IgG/IgM, mumps IgG/IgM, Borrelia
burgdorferi IgG/IgM, syphilis, HIV), and PCR analysis for neu-
rotropic viruses (HSV 1/2, VZV, CMV, Epstein-Barr virus,
enterovirus, human herpesvirus 6). Brain barrier dysfunction
and intrathecal synthesis of IgG were determined based on the
method of Reiber.6 The resulting data are presented in Reiber-
grams (figure 1), discriminating the QIgG from the IgG/serum
albumin ratio with hyperbolic reference range. The upper limit of
the reference range for an intact brain barrier function is age-
dependent and was calculated for each patient according to the
formula Qalb , (4 1 age/15) 3 103.7 Brain barrier dysfunction
was classified as mild (Qalb,103 103), moderate (Qalb 10–203
103), or severe (Qalb .20 3 103).8
Clinical data and CSF studies are given in the table.
MRI studies were performed on a 3T MRI system
(MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany)
using a standardized protocol including T2-weighted FLAIR echo
planar diffusion-weighted imaging including apparent diffusion coef-
ficient calculations and subsequent contrast-enhanced T1-weighted
and FLAIR sequences. The MRI data were analyzed with a struc-
tured reporting scheme independently by 2 reviewers unaware of
clinical detail and experienced with diagnostic and research studies
using postcontrast FLAIR MRI.
Statistical analysis was performed using SPSS version 22.0.0.0
(IBM, Armonk, NY). Group comparisons between patients with
and without leptomeningeal postcontrast FLAIR hyperintensity
regarding the severity of brain barrier dysfunction and CSF pro-
tein concentration, Qalb, and QIgG were calculated by Mann-
Whitney U test and 2-tailed Student t test, as appropriate. A
p value ,0.05 was considered to be statistically significant.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the local institutional
review board (Medizinische Ethikkommission II der Medizini-
schen Fakultät Mannheim, University of Heidelberg) and per-
formed in accordance with the ethical standards of the 1964
Declaration of Helsinki and its later amendments. Patient con-
sent was not required by our institutional review board due to the
retrospective nature of the study and the lack of patient
interaction.
RESULTS During the analyzed period, 15 patients
with a diagnosis of aseptic meningitis were examined
with a standardized 3T MRI protocol including post-
contrast FLAIR sequences and were potentially eligi-
ble for the study. One patient had to be excluded due
to incomplete CSF workup (Qalb missing).
Fourteen patients (8 men, age range 18–58 years,
all immunocompetent) were included in our study. All
patients presented with moderate to severe new-onset
headache; 8/14 had fever at presentation. In the clinical
course, 2 patients developed cranial nerve palsy (abdu-
cens nerve in 1, facial and vestibulocochlear nerve
in 1). One patient had new-onset epileptic seizures
(table).
On the initial MRI, no parenchymal signal altera-
tions were detected in precontrast sequences including
native FLAIR imaging in any of the patients. On post-
contrast FLAIR images, 7/14 patients showed lepto-
meningeal and/or sulcal contrast enhancement. In
4/7, a distinct leptomeningeal enhancement was pre-
sent along each cerebral lobe of both hemispheres
Figure 1 Reibergram (CSF/serum quotient diagram) of all included patients
Increasing albumin quotients reflect increasing blood-brain barrier dysfunction (x-axis). The
cutoff value for brain barrier dysfunction depends on the patient’s age and is therefore not
marked. On the y-axis, the blue line separates blood-borne IgG (below the line) and intrathecal
IgG synthesis (above the line). In our patient cohort, the CSF/serum albumin ratio (Qalb) was
significantly higher in patients with leptomeningeal enhancement on postcontrast fluid-
attenuated inversion recovery (FLAIR) imaging (red) than in those without leptomeningeal
enhancement (green). QIgG 5 CSF/serum IgG ratio.
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and the cerebellum; in 3/7, contrast enhancement was
more subtle and confined to the supratentorial lepto-
meninges. An example of ubiquitous contrast enhance-
ment of the meninges in a patient with meningitis
caused by VZV is given in figure 2. On contrast-
enhanced T1-weighted images, no parenchymal or
meningeal signal abnormalities were noted.
CSF analyses were performed a mean of 2.6 days
(62.1 days, range 0–8 days) prior to MRI and
showed lymphocytic pleocytosis (mean 206 cells/mL,
range 21–491) indicating aseptic meningitis in all
patients. There was no evidence of noninfectious
aseptic meningitis (postvaccinal, drugs, systemic
inflammatory disease, neoplastic disorder) in any of
the patients. A specific pathogen was detected in 7
patients. Of these, the 3 patients with leptomeningeal
enhancement were infected by Herpesviridae (VZV,
HSV2, CMV), whereas the 4 patients without lepto-
meningeal enhancement were positive for enterovirus
RNA. In relation to QIgG, none of the patients had
intrathecal synthesis of IgG antibodies. In 13/14 pa-
tients, Qalb accounted for a dysfunction of the brain
barriers that was classified as severe in 3/13, moderate
in 5/13, and mild in 5/13. Patients with leptomenin-
geal enhancement on postcontrast FLAIR imaging
showed significantly higher values of brain barrier
dysfunction (p 5 0.001). Leptomeningeal enhance-
ment on postcontrast FLAIR imaging was present in
all but 1 patient with moderate or severe brain barrier
dysfunction, whereas none of the patients with mild
or no disturbance of the brain barriers showed
contrast enhancement of the leptomeninges. The
presence of postcontrast leptomeningeal enhance-
ment was associated with higher Qalb (p 5 0.003)
and QIgG (p5 0.002) as well as a higher CSF protein
concentration (p 5 0.016). Leukocyte count did not
differ between patients with or without postcontrast
leptomeningeal enhancement (p 5 0.449). No post–
lumbar puncture complications occurred.
Clinical outcome was favorable, with resolution of
symptoms within 2 weeks in all but 1 patient. This
patient showed marked leptomeningeal enhancement
and moderate brain barrier disturbance on CSF anal-
ysis and had several complications, including sixth
cranial nerve palsy, undulating leukocyte count
.100/mL over 4 weeks, and increase of intracranial
pressure requiring continuous lumbar CSF drainage
for 7 days. In patients without leptomeningeal con-
trast enhancement, symptoms regressed more quickly
than in those showing postcontrast FLAIR signal
enhancement. As a result, the average length of hos-
pital stay was longer in patients with leptomeningeal
contrast enhancement (mean 19 days vs 7 days in
those without enhancing leptomeninges).
DISCUSSION Postcontrast FLAIR MRI sequences
have been shown to be valuable in the detection
and evaluation of different leptomeningeal diseases,
including subarachnoid hemorrhage, meningeosis,
and infectious meningitis.9 The nulling of the CSF
signal due to the inversion time facilitates an opti-
mized delineation of hyperintense pathology adjacent
Table Clinical data and CSF analyses of the included patients
Age, y, sex Etiology
Postcontrast
FLAIR
CSF WBC
count, n/mL CSF protein, mg/L Qalb QIgG
Brain barrier
dysfunction
27, F Viral, CMV 1 188 1,646.6 32.57 17.63 Severe
18, M ND 1 436 1,526.9 26.28 13.22 Severe
58, F ND 1 97 665.8 20.88 11.95 Severe
43, M ND 1 27 586.0 13 6.5 Moderate
54, M Viral, VZV 1 336 938.4 16.66 10.49 Moderate
31, M Viral, HSV2 1 491 879.6 15.2 7.32 Moderate
19, F ND 1 120 1,031.6 15.1 8.6 Moderate
52, M ND 2 98 1,059.7 16.4 8.19 Moderate
20, F ND 2 170 425.4 6.9 3.71 Mild
37, F Viral, enterovirus 2 66 541.1 9.1 4.07 Mild
39, M ND 2 48 468.6 7.49 3.9 Mild
18, M Viral, enterovirus 2 426 396.0 6.58 3.42 Mild
26, F Viral, enterovirus 2 366 493.6 8.78 4.41 Mild
42, M Viral, enterovirus 2 21 409.2 6.36 3.06 None
Abbreviations: CMV 5 cytomegalovirus; FLAIR 5 fluid-attenuated inversion recovery; HSV 5 herpes simplex virus; ND 5 not detectable; Qalb 5 CSF/serum
albumin ratio; QIgG 5 CSF/serum IgG ratio; VZV 5 varicella-zoster virus; WBC 5 white blood cell.
Brain barrier dysfunction was classified as mild (Qalb ,10 3 103), moderate (Qalb 10–20 3 103) or severe (Qalb .20 3 103).
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to the CSF in the sulcal and leptomeningeal space
while the T1 shortening in FLAIR sequences is
responsible for the highly sensitive delineation of
pathologic contrast enhancement following applica-
tion of gadolinium.10 In a large cohort of infants with
bacterial meningitis, contrast enhancement of the lep-
tomeninges was the most common pathologic finding
on MRI.11 From a pathophysiologic point of view,
leakage from damaged pial vessels leading to focal
extravasation of contrast agent into the CSF adjacent
to the brain is the likely cause for leptomeningeal
enhancement on FLAIR images.12 Contrast enhance-
ment of the leptomeninges on postcontrast FLAIR
sequences may thus be a surrogate for dysfunction
of the BCSFB and, more indirectly, a marker of
BBB dysfunction. In contrast to patients with ische-
mic stroke13 or cerebral amyloid angiopathy,14 in
whom localized brain barrier breakdown can be
observed, in patients with meningitis a more general-
ized pattern of contrast enhancement was seen,
involving both hemispheres and also the infratentorial
space in some patients.
We substantiate this hypothesis by correlating the
CSF findings with the presence of leptomeningeal
enhancement in patients with aseptic meningitis.
Contrast enhancement of the meninges occurred only
in patients with moderate to severe dysfunction of the
brain barriers and not in those with mild or no brain
barrier disturbance. Moreover, we demonstrate a pos-
itive correlation between the Qalb as a quantitative
marker for brain barrier dysfunction and the occur-
rence of leptomeningeal enhancement. Partly in line
with these findings, an association of log10-
transformed CSF protein and a leptomeningeal
enhancement score has been reported in patients with
infectious meningitis.15 However, log10-transformed
CSF protein is only an approximate value for brain
barrier disturbance, as it is not corrected for serum
protein content. The positive correlation may thus be
primarily based on the inclusion of patients with bac-
terial meningitis and marked CSF protein elevation.
Severe damage to the brain barriers, particularly as
seen in bacterial meningitis, may predispose to com-
plications and poor prognosis. Accordingly, a positive
correlation between the extent of leptomeningeal
enhancement on postcontrast FLAIR images and
the occurrence of complications has been demon-
strated in a study of 43 patients with meningitis of
various etiologies.15 However, complications affected
only 3 patients with bacterial meningitis and 1 patient
Figure 2 Exemplary MRI of a patient with contrast enhancement on postcontrast FLAIR
MRI of a 54-year-old patientwith viral meningitis caused by varicella-zoster virus. (A) Unenhanced precontrast fluid-attenuated
inversion recovery (FLAIR) images. On postcontrast FLAIR images (B), sulcal contrast enhancement and a fine hyperintense
lining can be seen, probably involving the leptomeninges in the absence of obvious white or gray matter lesions on both FLAIR
and postcontrast T1-weighted MRI (C). The magnified inserts highlight sulcal enhancement.
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with fungal meningitis, while the clinical course of
patients with viral meningitis was benign overall.
Our study focused on patients with aseptic menin-
gitis, characterized by mostly mild to moderate brain
barrier dysfunction. Of interest, although only
1 patient in our cohort had a complicated clinical
course, the presence of leptomeningeal enhancement
still accounted for a delayed resolution of clinical symp-
toms and a longer hospital stay. On the other hand, a
mild increase in brain barrier permeability in patients
with viral meningitis may be a precondition for lym-
phocyte infiltration and subsequent effective viral clear-
ance.16 Furthermore, the extent of brain barrier
dysfunction may vary depending on the specific viral
agent. Viral infections are characterized by individual
patterns of chemokine secretion that promote vascular
permeability.16 In our cohort, 3 patients with leptome-
ningeal enhancement were infected by Herpesviridae
(VZV, HSV2, CMV), coated double-stranded DNA
viruses, whereas 4 patients without leptomeningeal
enhancement were positive for enteroviruses, uncoated
double-stranded RNA viruses. Although data on HSV2
are lacking, HSV1 has been shown to affect the BBB
mainly via increased MMP2 and MMP9 activity, lead-
ing to collagen type IV degradation.17 Instead, in vitro
studies have shown that infection of choroid plexus cells
with echovirus 30, a member of the enterovirus family,
leads to enhanced secretion of CXCL1-3, chemoat-
tractants for T lymphocytes.18 This is motivation to
study the potential association between viral agents
and the occurrence of leptomeningeal enhancement
in future cohorts with more patients.
Because contrast-enhanced MRI was performed
after CSF analysis, it is theoretically possible that lepto-
meningeal enhancement was caused or enhanced by
the lumbar puncture. However, meningeal enhance-
ment seems to occur only in the case of post–lumbar
puncture headache or intracranial hypotension,19
which did not occur in any of our patients.
In patients with aseptic meningitis, leptomenin-
geal enhancement on postcontrast FLAIR images is
closely related to the extent of leakage of blood-
borne proteins into the CSF. Both leptomeningeal
enhancement and Qalb can thus serve as surrogate
markers for brain barrier dysfunction.
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